KRAS and cancer: We comprehensively evaluated pan-cancer somatic events to nominate biomarkers, and found that the subpopulation sensitive to both inhibitors was significantly enriched for BRAF mutants (P = 3.87e-14, hypergeometric test), while another subpopulation was exclusively sensitive to the MEK inhibitor and significantly enriched for KRAS mutations (P = 0.00589, hypergeometric test).